

別添 B

Tables

1-1	Clinical signs in males (Administration period)	46
1-2	Clinical signs in females (Administration period)	47
1-3	Clinical signs in males (Recovery period)	48
1-4	Clinical signs in females (Recovery period)	49
2-1	Body weight of males	50
2-2	Body weight gain of males	51
2-3	Body weight of females – Before mating	52
2-4	Body weight gain of females – Before mating	53
2-5	Body weight of dams (F0) – Gestation period	54
2-6	Body weight gain of dams (F0) – Gestation period	55
2-7	Body weight of dams (F0) – Lactation period	56
2-8	Body weight gain of dams (F0) – Lactation period	57
3-1	Food consumption in males	58
3-2	Food consumption in females – Before mating	59
3-3	Food consumption in dams (F0) – Gestation period	60
3-4	Food consumption in dams (F0) – Lactation period	61
4	Mating performance	62
5	Abbreviations of hematology parameters	63
5-1	Hematology in males (End of drug administration)	64
5-2	Hematology in females (End of drug administration)	65
5-3	Hematology in males (End of recovery test)	66
5-4	Hematology in females (End of recovery test)	67
6	Abbreviations of blood chemistry parameters	68
6-1	Blood chemistry in males (End of drug administration)	69
6-2	Blood chemistry in females (End of drug administration)	70
6-3	Blood chemistry in males (End of recovery test)	71
6-4	Blood chemistry in females (End of recovery test)	72
7-1	Gross pathological findings in males (End of drug administration)	73
7-2	Gross pathological findings in females (End of drug administration)	74
7-3	Gross pathological findings in males (End of recovery test)	75
7-4	Gross pathological findings in females (End of recovery test)	76

8	Abbreviations of organ weights	77
8-1	Organ weight in males (End of drug administration)	78
8-2	Organ weight in females (End of drug administration)	79
8-3	Organ weight in males (End of recovery test)	80
8-4	Organ weight in females (End of recovery test)	81
8-5	Relative organ weight in males (End of drug administration)	82
8-6	Relative organ weight in females (End of drug administration)	83
8-7	Relative organ weight in males (End of recovery test)	84
8-8	Relative organ weight in females (End of recovery test)	85
9-1	Histopathological findings in males [H.E. staining] (End of drug administration)	86
9-2	Histopathological findings in females [H.E. staining] (End of drug administration)	88
9-3	Histopathological findings in males [Testis, PAS-Hematoxylin staining] (End of drug administration)	90
9-4	Histopathological findings in animals [Liver, H.E. staining] (End of drug administration)	91
10-1	Clinical signs in pups (F1) – Lactation period	92
10-2	External findings at birth (F1)	93
11	Development of pups (F1) up to Day 4 after birth	94
12	Body weight of pups (F1) – Lactation period	95
13	Gross pathological findings in pups (F1) at Day 4 after birth	96

Table 1-1 Clinical signs in males

Study No. : SBL75-31

(Administration period)

Dose (mg/kg)	Control	2.5	25	250
No. of animals	15	10	10	15
Normal	15	10	10	15

Table 1-2 Clinical signs in females (Administration period)

Study No. : SBL75-31

Dose (mg/kg)	Control	2.5	25	250
Before mating				
No. of animals	15	10	10	15
Normal	15	10	10	15
Mating period				
No. of animals	10	10	10	10
Normal	10	10	10	10
Gestation period				
No. of animals	9	9 ¹⁾	10	10
Normal	9	9	10	10
Lactation period				
No. of animals	9	10	10	10
Normal	9	10	10	10

1): Except an animal in which copulation was not confirmed.

Table 1-3 Clinical signs in males

Study No. : SBL75-31

(Recovery period)

Dose (mg/kg)	Control	250
No. of animals	5	5
Normal	5	5

Table 1-4 Clinical signs in females

Study No. : SBL75-31

(Recovery period)

Dose (mg/kg)	Control	250
No. of animals	5	5
Normal	5	5

Table 2-1 Body weight of males (mean \pm S.D. , g)

Study No. : SBL75-31

Dose (mg/kg) Day	Control	2.5	25	250
(Administration period)				
0	187.9 \pm 4.3 (15)	187.0 \pm 4.6 (10)	185.2 \pm 3.7 (10)	187.7 \pm 6.0 (15)
3	213.4 \pm 6.9 (15)	212.4 \pm 5.9 (10)	212.0 \pm 5.7 (10)	215.3 \pm 7.6 (15)
7	245.9 \pm 9.8 (15)	246.8 \pm 7.5 (10)	245.6 \pm 7.9 (10)	248.5 \pm 11.2 (15)
10	270.8 \pm 13.2 (15)	270.9 \pm 9.4 (10)	267.5 \pm 14.7 (10)	272.1 \pm 14.7 (15)
14	299.5 \pm 15.9 (15)	299.3 \pm 13.1 (10)	293.4 \pm 20.0 (10)	301.4 \pm 18.9 (15)
17	319.1 \pm 18.0 (15)	316.4 \pm 15.1 (10)	310.8 \pm 24.8 (10)	319.0 \pm 20.3 (15)
21	340.6 \pm 20.4 (15)	339.9 \pm 17.9 (10)	332.6 \pm 28.4 (10)	341.5 \pm 23.5 (15)
24	358.1 \pm 22.3 (15)	355.7 \pm 19.6 (10)	346.5 \pm 30.9 (10)	356.6 \pm 24.2 (15)
28	377.1 \pm 24.0 (15)	374.9 \pm 22.4 (10)	364.2 \pm 35.9 (10)	373.7 \pm 26.0 (15)
31	385.2 \pm 24.7 (15)	386.2 \pm 24.8 (10)	368.9 \pm 36.5 (10)	380.5 \pm 28.1 (15)
35	402.8 \pm 25.3 (15)	403.1 \pm 24.4 (10)	383.6 \pm 36.4 (10)	394.7 \pm 30.9 (15)
38	412.4 \pm 25.0 (15)	415.4 \pm 26.4 (10)	395.3 \pm 38.2 (10)	406.4 \pm 31.6 (15)
42	428.7 \pm 26.5 (15)	432.4 \pm 25.5 (10)	413.0 \pm 40.7 (10)	421.1 \pm 32.1 (15)
45	438.7 \pm 27.5 (15)	442.3 \pm 27.5 (10)	421.9 \pm 40.1 (10)	430.7 \pm 35.2 (15)
49	449.6 \pm 30.5 (15)	452.2 \pm 29.3 (10)	430.7 \pm 39.3 (10)	439.3 \pm 34.9 (15)
52	455.8 \pm 31.5 (15)	459.5 \pm 30.6 (10)	438.8 \pm 41.2 (10)	444.7 \pm 34.4 (15)
(Recovery period)				
56	480.0 \pm 23.7 (5)			468.6 \pm 30.1 (5)
59	489.6 \pm 22.4 (5)			477.6 \pm 29.1 (5)
63	499.0 \pm 23.1 (5)			485.4 \pm 28.6 (5)
66	505.6 \pm 19.8 (5)			493.2 \pm 25.6 (5)
70	474.2 \pm 22.8 (5)			457.0 \pm 25.2 (5)

Not significantly different from the control group by Dunnet's type test / Dunnet's test.
 Not significantly different from the control group by t-test.

Day 70 : Animals that were fasted

Table 2-2 Body weight gain of males (mean \pm S.D. , g)

Study No. : SBL75-31

Dose (mg/kg) Day	Control	2.5	25	250
(Administration period)				
0- 3	25.5 \pm 3.3 (15)	25.4 \pm 2.9 (10)	26.8 \pm 3.0 (10)	27.7 \pm 2.9 (15)
3- 7	32.5 \pm 3.9 (15)	34.4 \pm 2.8 (10)	33.6 \pm 4.2 (10)	33.1 \pm 4.6 (15)
7-10	24.9 \pm 5.4 (15)	24.1 \pm 4.8 (10)	21.9 \pm 7.5 (10)	23.7 \pm 5.3 (15)
10-14	28.7 \pm 4.9 (15)	28.4 \pm 5.7 (10)	25.9 \pm 6.6 (10)	29.3 \pm 5.4 (15)
14-17	19.5 \pm 4.1 (15)	17.1 \pm 3.7 (10)	17.4 \pm 5.2 (10)	17.6 \pm 3.8 (15)
17-21	21.5 \pm 3.9 (15)	23.5 \pm 5.3 (10)	21.8 \pm 4.3 (10)	22.5 \pm 4.3 (15)
21-24	17.5 \pm 4.0 (15)	15.8 \pm 2.9 (10)	13.9 \pm 3.8 (10)	15.1 \pm 4.6 (15)
24-28	19.1 \pm 4.0 (15)	19.2 \pm 4.5 (10)	17.7 \pm 6.4 (10)	17.1 \pm 5.6 (15)
28-31	8.1 \pm 5.8 (15)	11.3 \pm 4.2 (10)	4.7 \pm 5.0 (10)	6.8 \pm 4.7 (15)
31-35	17.6 \pm 4.3 (15)	16.9 \pm 2.0 (10)	14.7 \pm 4.2 (10)	14.1 \pm 4.5 (15)
35-38	9.6 \pm 2.3 (15)	12.3 \pm 5.3 (10)	11.7 \pm 3.8 (10)	11.7 \pm 4.0 (15)
38-42	16.3 \pm 4.7 (15)	17.0 \pm 3.2 (10)	17.7 \pm 5.1 (10)	14.7 \pm 6.0 (15)
42-45	9.9 \pm 5.5 (15)	9.9 \pm 5.0 (10)	8.9 \pm 1.9 (10)	9.6 \pm 4.2 (15)
45-49	10.9 \pm 5.4 (15)	9.9 \pm 4.3 (10)	8.8 \pm 4.3 (10)	8.7 \pm 3.2 (15)
49-52	6.2 \pm 4.1 (15)	7.3 \pm 3.3 (10)	8.1 \pm 3.3 (10)	5.4 \pm 4.3 (15)
52-56	11.6 \pm 4.7 (5)			10.8 \pm 6.1 (5)
(Recovery period)				
56-59	9.6 \pm 2.2 (5)			9.0 \pm 5.4 (5)
59-63	9.4 \pm 5.5 (5)			7.8 \pm 5.4 (5)
63-66	6.6 \pm 4.8 (5)			7.8 \pm 5.1 (5)
66-70	-31.4 \pm 3.6 (5)			-36.2 \pm 7.3 (5)

Not significantly different from the control group by Dunnet's type test / Dunnet's test.
 Not significantly different from the control group by t-test.

Day 70 : Animals that were fasted

Table 2-3 Body weight of females - Before mating (mean \pm S.D. , g)

Study No. : SBL75-31

Dose (mg/kg) Day	Control	2.5	25	250
(Administration period)				
0	151.9 \pm 6.3 (15)	154.7 \pm 7.5 (10)	153.8 \pm 5.4 (10)	153.1 \pm 7.0 (15)
3	163.5 \pm 7.3 (15)	165.1 \pm 9.4 (10)	165.4 \pm 6.9 (10)	163.8 \pm 7.5 (15)
7	175.8 \pm 9.8 (15)	177.1 \pm 11.6 (10)	178.9 \pm 10.5 (10)	176.9 \pm 10.2 (15)
10	186.7 \pm 12.3 (15)	188.4 \pm 14.7 (10)	192.4 \pm 10.8 (10)	187.5 \pm 10.3 (15)
14	197.2 \pm 15.4 (15)	201.6 \pm 18.3 (10)	204.8 \pm 12.8 (10)	198.6 \pm 11.7 (15)
17	205.0 \pm 16.2 (15)	209.3 \pm 19.0 (10)	214.1 \pm 14.0 (10)	206.4 \pm 12.7 (15)
21	215.7 \pm 18.2 (15)	224.4 \pm 20.9 (10)	226.3 \pm 12.7 (10)	219.3 \pm 13.8 (15)
24	223.5 \pm 19.5 (15)	232.0 \pm 21.7 (10)	232.8 \pm 13.0 (10)	226.7 \pm 14.0 (15)
28	233.2 \pm 20.9 (15)	243.0 \pm 23.3 (10)	243.5 \pm 12.3 (10)	237.2 \pm 15.3 (15)
31	238.6 \pm 22.7 (5)			246.4 \pm 17.3 (5)
35	247.0 \pm 23.3 (5)			254.8 \pm 16.8 (5)
38	251.4 \pm 29.2 (5)			258.4 \pm 18.5 (5)
42	256.6 \pm 27.0 (5)			266.6 \pm 18.7 (5)
45	261.8 \pm 27.5 (5)			273.8 \pm 18.0 (5)
49	265.6 \pm 27.4 (5)			277.6 \pm 18.4 (5)
52	270.0 \pm 22.5 (5)			281.6 \pm 20.5 (5)
(Recovery period)				
56	277.2 \pm 22.8 (5)			288.2 \pm 15.7 (5)
59	280.6 \pm 23.9 (5)			292.8 \pm 18.3 (5)
63	285.2 \pm 22.4 (5)			298.0 \pm 15.9 (5)
66	285.8 \pm 26.5 (5)			305.4 \pm 17.8 (5)
70	268.2 \pm 21.4 (5)			283.0 \pm 17.5 (5)

Not significantly different from the control group by Dunnet's type test / Dunnet's test.
 Not significantly different from the control group by t-test.

Day 70 : Animals that were fasted

Table 2-4 Body weight gain of females - Before mating (mean \pm S.D. , g)

Study No. : SBL75-31

Dose (mg/kg) Day	Control	2.5	25	250
(Administration period)				
0- 3	11.7 \pm 3.5 (15)	10.4 \pm 3.7 (10)	11.6 \pm 3.9 (10)	10.7 \pm 3.3 (15)
3- 7	12.3 \pm 3.6 (15)	12.0 \pm 3.8 (10)	13.5 \pm 5.1 (10)	13.1 \pm 4.3 (15)
7-10	10.9 \pm 4.1 (15)	11.3 \pm 4.3 (10)	13.5 \pm 4.6 (10)	10.6 \pm 2.8 (15)
10-14	10.5 \pm 4.3 (15)	13.2 \pm 5.7 (10)	12.4 \pm 4.2 (10)	11.1 \pm 2.8 (15)
14-17	7.8 \pm 3.5 (15)	7.7 \pm 4.5 (10)	9.3 \pm 3.2 (10)	7.8 \pm 5.2 (15)
17-21	10.7 \pm 4.3 (15)	15.1 \pm 3.8* (10)	12.2 \pm 3.6 (10)	12.9 \pm 4.2 (15)
21-24	7.8 \pm 3.2 (15)	7.6 \pm 3.9 (10)	6.5 \pm 3.7 (10)	7.5 \pm 4.4 (15)
24-28	9.7 \pm 2.7 (15)	11.0 \pm 4.1 (10)	10.7 \pm 2.9 (10)	10.5 \pm 3.5 (15)
28-31	3.8 \pm 3.1 (5)			6.0 \pm 4.8 (5)
31-35	8.4 \pm 2.6 (5)			8.4 \pm 1.5 (5)
35-38	4.4 \pm 6.1 (5)			3.6 \pm 4.5 (5)
38-42	5.2 \pm 2.6 (5)			8.2 \pm 3.1 (5)
42-45	5.2 \pm 4.4 (5)			7.2 \pm 5.1 (5)
45-49	3.8 \pm 2.8 (5)			3.8 \pm 4.2 (5)
49-52	4.4 \pm 5.6 (5)			4.0 \pm 5.7 (5)
52-56	7.2 \pm 2.2 (5)			6.6 \pm 5.0 (5)
(Recovery period)				
56-59	3.4 \pm 2.6 (5)			4.6 \pm 3.4 (5)
59-63	4.6 \pm 3.0 (5)			5.2 \pm 3.5 (5)
63-66	0.6 \pm 4.3 (5)			7.4 \pm 4.3 (5)
66-70	-17.6 \pm 6.0 (5)			-22.4 \pm 3.2 (5)

* P<0.05 : Significantly different from the control group by Dunnet's type test / Dunnet's test.
Not significantly different from the control group by t-test.

Day 70 : Animals that were fasted

Table 2-5

Body weight of dams (F0) - Gestation period (mean \pm S.D. , g)

Study No. : SBL75-31

Dose (mg/kg) Days of gestation	Control	2.5	25	250
0	237.8 \pm 22.9 (9)	248.1 \pm 17.6 (9)	247.5 \pm 13.6 (10)	241.0 \pm 16.2 (10)
7	273.2 \pm 27.4 (9)	284.1 \pm 20.8 (9)	281.3 \pm 14.6 (10)	280.5 \pm 17.1 (10)
14	311.9 \pm 28.0 (9)	326.0 \pm 23.9 (9)	321.8 \pm 14.8 (10)	321.1 \pm 22.9 (10)
20	392.6 \pm 35.2 (9)	405.0 \pm 28.0 (9)	396.3 \pm 19.8 (10)	398.7 \pm 34.6 (10)

() : No. of dams

Not significantly different from the control group by Dunnet's type test / Dunnet's test

Table 2-6

Body weight gain of dams (F0) - Gestation period (mean \pm S.D. , g)

Study No. : SBL75-31

Dose (mg/kg) Days of gestation	Control	2.5	25	250
0- 7	35.4 \pm 7.7 (9)	36.0 \pm 6.6 (9)	33.8 \pm 5.4 (10)	39.5 \pm 7.2 (10)
7-14	38.7 \pm 8.2 (9)	41.9 \pm 5.9 (9)	40.5 \pm 5.8 (10)	40.6 \pm 7.1 (10)
14-20	80.7 \pm 12.6 (9)	79.0 \pm 9.7 (9)	74.5 \pm 10.5 (10)	77.6 \pm 15.4 (10)

() : No. of dams

Not significantly different from the control group by Dunnet's type test / Dunnet's test

Table 2-7

Body weight of dams (F0) - Lactation period (mean \pm S.D. ; g)

Study No. : SBL75-31

Dose (mg/kg) Days after delivery	Control	2.5	25	250
0	281.0 \pm 28.6 (9)	293.3 \pm 28.2 (10)	287.2 \pm 15.1 (10)	294.2 \pm 19.0 (10)
3	306.4 \pm 33.8 (9)	311.6 \pm 23.8 (10)	313.3 \pm 20.2 (10)	313.5 \pm 15.5 (10)
4	276.9 \pm 36.5 (9)	281.6 \pm 31.2 (10)	280.1 \pm 20.2 (10)	280.3 \pm 17.0 (10)

() : No. of dams

Not significantly different from the control group by Dunnet's type test / Dunnet's test

Day 4 : Animals that were fasted

Table 2-8 Body weight gain of dams (F0) - Lactation period (mean \pm S.D. , g) Study No. : SBL75-31

Dose (mg/kg) Days after delivery	Control	2.5	25	250
0- 3	25.4 \pm 12.4 (9)	18.3 \pm 11.4 (10)	26.1 \pm 10.5 (10)	19.3 \pm 7.9 (10)
3- 4	-29.6 \pm 7.0 (9)	-30.0 \pm 9.2 (10)	-33.2 \pm 7.0 (10)	-33.2 \pm 7.1 (10)

() : No. of dams

Not significantly different from the control group by Dunnett's type test / Dunnett's test

Day 4 : Animal that were fasted

Table 3-1 Food consumption in males (mean \pm S.D. , g/day)

Study No. : SBL75-31

Dose (mg/kg) Day	Control	2.5	25	250
(Administration period)				
0- 1	23.9 \pm 2.0 (15)	24.3 \pm 1.9 (10)	24.0 \pm 1.8 (10)	24.7 \pm 2.1 (15)
3- 4	26.3 \pm 2.5 (15)	25.7 \pm 2.7 (10)	25.8 \pm 1.9 (10)	25.7 \pm 1.7 (15)
7- 8	27.9 \pm 2.5 (15)	26.6 \pm 3.0 (10)	27.9 \pm 3.6 (10)	27.9 \pm 2.3 (15)
10-11	30.0 \pm 3.3 (15)	27.9 \pm 2.6 (10)	27.8 \pm 4.1 (10)	30.5 \pm 3.2 (15)
14-15	28.4 \pm 3.5 (15)	25.8 \pm 2.5 (10)	27.4 \pm 3.7 (10)	28.5 \pm 3.5 (15)
17-18	29.3 \pm 3.2 (15)	27.3 \pm 1.8*	27.3 \pm 3.7 (10)	29.7 \pm 1.8 (15)
21-22	30.4 \pm 2.7 (15)	28.9 \pm 3.0 (10)	27.6 \pm 3.5 (10)	29.9 \pm 2.5 (15)
24-25	29.5 \pm 3.2 (15)	29.4 \pm 3.2 (10)	28.6 \pm 3.4 (10)	29.7 \pm 1.8 (15)
28-29	33.2 \pm 1.8 (5)	(0)	(0)	30.4 \pm 1.5* (5)
31-32	32.2 \pm 2.9 (5)	(0)	(0)	30.4 \pm 2.9 (5)
35-36	29.6 \pm 1.5 (5)	(0)	(0)	30.2 \pm 2.0 (5)
38-39	33.0 \pm 2.3 (5)	(0)	(0)	30.6 \pm 3.2 (5)
42-43	31.4 \pm 1.8 (5)	(0)	(0)	32.2 \pm 2.4 (5)
45-46	33.8 \pm 2.6 (5)	(0)	(0)	32.0 \pm 3.7 (5)
49-50	27.0 \pm 2.5 (5)	(0)	(0)	28.4 \pm 4.7 (5)
52-53	29.2 \pm 1.5 (5)	(0)	(0)	30.2 \pm 2.0 (5)
(Recovery period)				
56-57	31.6 \pm 1.9 (5)	(0)	(0)	32.2 \pm 2.4 (5)
59-60	30.0 \pm 1.0 (5)	(0)	(0)	32.0 \pm 1.0 (5)
63-64	33.2 \pm 0.8 (5)	(0)	(0)	32.4 \pm 2.7 (5)
66-67	31.8 \pm 2.2 (5)	(0)	(0)	32.0 \pm 3.1 (5)

() : No. of animals

* P<0.05 : Significantly different from the control group by Dunnet's type test / Dunnet's test.

Not significantly different from the control group by t-test.

Table 3-2 Food consumption in females - Before mating (mean \pm S.D. , g/day)

Study No. : SBL75-31

Dose (mg/kg) Day	Control	2.5	25	250
(Administration period)				
0- 1	18.0 \pm 2.3 (15)	17.8 \pm 1.8 (10)	18.8 \pm 2.1 (10)	18.5 \pm 2.2 (15)
3- 4	19.0 \pm 2.2 (15)	19.6 \pm 3.9 (10)	19.8 \pm 1.9 (10)	19.9 \pm 3.3 (15)
7- 8	19.6 \pm 2.6 (15)	20.6 \pm 3.0 (10)	20.2 \pm 1.6 (10)	19.0 \pm 2.6 (15)
10-11	20.4 \pm 2.6 (15)	20.9 \pm 4.9 (10)	19.4 \pm 2.3 (10)	20.1 \pm 3.3 (15)
14-15	19.0 \pm 2.1 (15)	17.9 \pm 3.2 (10)	19.0 \pm 2.8 (10)	19.1 \pm 2.3 (15)
17-18	19.9 \pm 4.0 (15)	19.3 \pm 2.4 (10)	21.4 \pm 1.8 (10)	21.2 \pm 2.7 (15)
21-22	20.3 \pm 3.7 (15)	20.2 \pm 2.9 (10)	21.1 \pm 1.9 (10)	20.1 \pm 2.1 (15)
24-25	19.9 \pm 3.1 (15)	22.2 \pm 4.7 (10)	21.9 \pm 3.5 (10)	21.6 \pm 3.5 (15)
28-29	21.0 \pm 2.3 (5)	(0)	(0)	19.8 \pm 3.4 (5)
31-32	19.4 \pm 1.3 (5)	(0)	(0)	22.4 \pm 2.1* (5)
35-36	19.8 \pm 1.3 (5)	(0)	(0)	21.0 \pm 1.2 (5)
38-39	21.0 \pm 2.0 (5)	(0)	(0)	24.0 \pm 2.6 (5)
42-43	21.8 \pm 2.2 (5)	(0)	(0)	21.6 \pm 2.2 (5)
45-46	22.4 \pm 4.2 (5)	(0)	(0)	22.2 \pm 2.0 (5)
49-50	19.2 \pm 4.2 (5)	(0)	(0)	19.8 \pm 3.9 (5)
52-53	20.0 \pm 2.3 (5)	(0)	(0)	21.2 \pm 1.6 (5)
(Recovery period)				
56-57	21.0 \pm 1.9 (5)	(0)	(0)	23.8 \pm 2.4 (5)
59-60	22.6 \pm 2.6 (5)	(0)	(0)	22.0 \pm 2.5 (5)
63-64	22.4 \pm 2.5 (5)	(0)	(0)	23.4 \pm 2.1 (5)
66-67	22.4 \pm 2.5 (5)	(0)	(0)	23.0 \pm 1.2 (5)

() : No. of animals

* P<0.05 : Significantly different from the control group by Dunnet's type test / Dunnet's test.
Not significantly different from the control group by t-test.

Table 3-3 Food consumption in dams (F0) - Gestation period (mean \pm S.D. , g/day) Study No. : SBL75-31

Dose (mg/kg) Days of gestation	Control	2.5	25	250
0- 1	20.9 \pm 3.9 (9)	20.8 \pm 2.1 (9)	20.3 \pm 3.1 (10)	20.8 \pm 3.3 (10)
3- 4	22.6 \pm 5.3 (9)	24.6 \pm 3.8 (9)	24.8 \pm 2.7 (10)	26.1 \pm 2.5 (10)
6- 7	25.3 \pm 3.5 (9)	26.1 \pm 2.0 (9)	24.3 \pm 2.9 (10)	26.6 \pm 2.2 (10)
10-11	26.7 \pm 3.6 (9)	28.0 \pm 2.7 (9)	27.7 \pm 1.9 (10)	28.2 \pm 2.3 (10)
14-15	26.1 \pm 3.0 (9)	28.2 \pm 4.5 (9)	28.1 \pm 2.1 (10)	25.9 \pm 2.5 (10)
17-18	29.4 \pm 2.9 (9)	28.7 \pm 3.0 (9)	30.1 \pm 2.7 (10)	29.8 \pm 2.4 (10)
19-20	27.1 \pm 3.8 (9)	27.7 \pm 3.5 (9)	28.2 \pm 2.5 (10)	29.1 \pm 2.7 (10)

() : No. of dams
 Not significantly different from the control group by Dunnet's type test / Dunnet's test

Table 3-4 Food consumption in dams (F0) - Lactation period (mean \pm S.D. , g/day) Study No. : SBL75-31

Dose (mg/kg) Days after delivery	Control	2.5	25	250
0- 1	13.8 \pm 8.9 (9)	12.8 \pm 7.4 (10)	12.9 \pm 9.8 (10)	15.0 \pm 8.7 (10)
2- 3	38.1 \pm 5.2 (9)	33.7 \pm 4.2 (10)	35.5 \pm 8.6 (10)	34.2 \pm 4.4 (10)

() : No. of dams

Not significantly different from the control group by Dunnet's type test / Dunnet's test

Table 4 Mating performance

Study No. : SBL75-31

Dose : (mg/kg)		Control	2.5	25	250
No. of pairs used for mating	(a)	10	10	10	10
No. of pairs with successful copulation	(b)	9	10	10	10
Copulatory index (%)	(b/a)	90.0	100.0	100.0	100.0
Mean copulatory interval (days , mean±S.D.)		4.9±4.4	3.4±3.8	2.7±1.3	2.8±1.5
No. of fertile pairs	(c)	9	10	10	10
Fertility index (%)	(c/b)	100.0	100.0	100.0	100.0

Not significantly different from the control group by Dunnet's type test / Dunnet's test.
 Not significantly different from the control group by Fisher's exact test.

Table 5 Abbreviations of hematology parameters

Hematology

RBC	($10^6/\text{mm}^3$)	Number of red blood cells
WBC	($10^3/\text{mm}^3$)	Number of white blood cells
Ht	(%)	Hematocrit value
Hb	(g/dL)	Hemoglobin concentration
Plat.	($10^3/\text{mm}^3$)	Number of blood platelets
MCV	(fL)	Mean corpuscular volume
MCH	(pg)	Mean corpuscular hemoglobin
MCHC	(g/dL)	Mean corpuscular hemoglobin concentration
Ret.(%)	(%)	Reticulocyte ratio
Hemogram		
Eosino.	($10^3/\text{mm}^3$)	Number of eosinophilic leukocytes
Eosino.	(%)	Eosinophilic leukocyte ratio
Baso.	($10^3/\text{mm}^3$)	Number of basophilic leukocytes
Baso.	(%)	Basophilic leukocyte ratio
Mono.	($10^3/\text{mm}^3$)	Number of monocytes
Mono.	(%)	Monocyte ratio
Lymph.	($10^3/\text{mm}^3$)	Number of lymphocytes
Lymph.	(%)	Lymphocyte ratio
Neutro.	($10^3/\text{mm}^3$)	Number of neutrophilic leukocytes
Neutro.	(%)	Neutrophilic leukocyte ratio
LUC	($10^3/\text{mm}^3$)	Number of large unstained cells
LUC	(%)	Large unstained cell ratio
Blood coagulation test		
PT	(Sec)	Prothrombin time
APTT	(Sec)	Activated partial thromboplastin time

Table 5-1

Hematology in males (End of drug administration)

Study No. : SBL75-31

Dose(mg/kg)		Control	2.5	25	250
N		5	5	5	5
RBC	($10^6/\text{mm}^3$)	8.184±0.323	7.946±0.307	8.068±0.304	7.634±0.364*
WBC	($10^3/\text{mm}^3$)	9.414±1.059	8.218±2.935	8.102±2.368	8.936±1.133
Ht	(%)	45.56±1.90	44.32±0.91	44.68±2.24	42.70±1.68
Hb	(g/dL)	15.24±0.38	14.86±0.54	15.12±0.86	14.22±0.70
Plat.	($10^3/\text{mm}^3$)	1063.2±109.9	1145.2±134.1	1201.8±119.3	1204.8±107.7
MCV	(fL)	55.70±2.34	55.84±1.45	55.36±0.86	55.94±0.72
MCH	(pg)	18.66±0.70	18.68±0.79	18.72±0.43	18.60±0.27
MCHC	(g/dL)	33.54±0.69	33.50±0.71	33.82±0.37	33.26±0.44
Ret.	(%)	2.60±0.34	2.74±0.57	3.00±0.40	3.02±0.44
Eosino.	($10^3/\text{mm}^3$)	0.102±0.036	0.118±0.024	0.072±0.028	0.106±0.032
Eosino.	(%)	1.08±0.42	1.62±0.70	0.88±0.13	1.22±0.38
Baso.	($10^3/\text{mm}^3$)	0.018±0.004	0.016±0.009	0.014±0.005	0.012±0.004
Baso.	(%)	0.18±0.04	0.16±0.09	0.16±0.05	0.12±0.04
Mono.	($10^3/\text{mm}^3$)	0.158±0.078	0.114±0.025	0.100±0.062	0.148±0.008
Mono.	(%)	1.64±0.61	1.58±0.73	1.20±0.35	1.68±0.30
Lymph.	($10^3/\text{mm}^3$)	8.064±0.827	6.770±2.978	6.486±2.114	7.050±1.135
Lymph.	(%)	85.78±2.26	80.58±7.34	79.64±3.66	78.64±4.29
Neutro.	($10^3/\text{mm}^3$)	0.990±0.238	1.124±0.345	1.360±0.299	1.512±0.277*
Neutro.	(%)	10.48±1.99	14.96±5.91	17.30±3.71	17.18±4.23
LUC	($10^3/\text{mm}^3$)	0.082±0.008	0.078±0.024	0.068±0.040	0.104±0.078
LUC	(%)	0.86±0.05	1.10±0.51	0.82±0.43	1.10±0.74
PT	(Sec)	8.52±0.42	9.50±0.97	9.20±0.57	8.50±0.58
APTT	(Sec)	20.10±0.77	20.94±0.65	18.34±0.98**	18.18±0.71**

Values are expressed as the mean + S.D.

* $p < 0.05$, ** $p < 0.01$: significantly different from the control group by Dunnet's type test / Dunnet's test.

Table 5-2 Hematology in females (End of drug administration)

Study No. : SBL75-31

Dose (mg/kg)		Control	2.5	25	250
N		5	5	5	5
RBC	($10^6/\text{mm}^3$)	6.810±0.489	6.904±0.360	6.816±0.138	6.500±0.243
WBC	($10^3/\text{mm}^3$)	5.952±0.959	6.188±1.379	6.344±1.463	5.050±0.711
Ht	(%)	40.16±2.06	41.08±1.68	39.40±1.19	39.58±2.33
Hb	(g/dL)	13.38±0.66	13.98±0.75	13.14±0.36	13.36±0.77
Plat.	($10^3/\text{mm}^3$)	1468.0±237.3	1517.6±44.2	1496.0±207.7	1502.6±156.5
MCV	(fL)	59.08±2.35	59.58±1.84	57.80±2.12	60.90±1.46
MCH	(pg)	19.70±0.82	20.26±0.46	19.28±0.65	20.54±0.50
MCHC	(g/dL)	33.34±0.21	34.00±0.59	33.40±0.73	33.74±0.37
Ret.	(%)	6.48±2.55	4.88±1.04	4.48±1.28	6.28±2.55
Eosino.	($10^3/\text{mm}^3$)	0.068±0.019	0.048±0.019	0.038±0.016*	0.038±0.018*
Eosino.	(%)	1.10±0.31	0.82±0.32	0.62±0.24	0.74±0.35
Baso.	($10^3/\text{mm}^3$)	0.004±0.005	0.008±0.004	0.010±0.007	0.000±0.000
Baso.	(%)	0.08±0.04	0.10±0.07	0.10±0.07	0.08±0.04
Mono.	($10^3/\text{mm}^3$)	0.088±0.053	0.058±0.027	0.078±0.036	0.072±0.044
Mono.	(%)	1.44±0.78	0.96±0.32	1.18±0.30	1.38±0.86
Lymph.	($10^3/\text{mm}^3$)	3.702±0.766	4.614±1.065	4.634±1.454	3.408±0.151
Lymph.	(%)	61.98±4.94	74.58±6.18	71.96±8.38	68.72±11.35
Neutro.	($10^3/\text{mm}^3$)	2.052±0.302	1.432±0.505	1.546±0.352	1.500±0.766
Neutro.	(%)	34.74±4.38	23.08±5.78	25.52±8.49	28.50±11.13
LUC	($10^3/\text{mm}^3$)	0.038±0.015	0.030±0.007	0.036±0.015	0.032±0.013
LUC	(%)	0.66±0.24	0.50±0.12	0.60±0.23	0.58±0.23
PT	(Sec)	7.38±0.29	7.28±0.19	7.42±0.27	6.94±0.32
APTT	(Sec)	18.56±1.19	19.14±1.92	18.82±0.25	14.74±3.36

Values are expressed as the mean ± S.D.

* P<0.05 : Significantly different from the control group by Dunnet's type test / Dunnet's test.

Table 5-3

Hematology in males (End of recovery test)

Study No. : SBL75-31

Dose (mg/kg)		Control	2.5	25	250
N		5	0	0	5
RBC	($10^6/\text{mm}^3$)	8.866±0.544			8.342±0.406
WBC	($10^3/\text{mm}^3$)	8.506±1.532			9.516±1.568
Ht	(%)	47.26±2.39			45.66±1.12
Hb	(g/dL)	15.76±0.74			15.10±0.32
Plat.	($10^3/\text{mm}^3$)	1081.0±73.3			1406.4±218.2*
MCV	(fL)	53.36±1.25			54.86±3.31
MCH	(pg)	17.80±0.46			18.14±0.95
MCHC	(g/dL)	33.36±0.17			33.06±0.69
Ret.	(%)	2.44±0.38			2.80±0.16
Eosino.	($10^3/\text{mm}^3$)	0.100±0.052			0.092±0.031
Eosino.	(%)	1.16±0.55			0.98±0.45
Baso.	($10^3/\text{mm}^3$)	0.008±0.004			0.016±0.009
Baso.	(%)	0.10±0.07			0.18±0.08
Mono.	($10^3/\text{mm}^3$)	0.116±0.041			0.174±0.046
Mono.	(%)	1.40±0.56			1.82±0.39
Lymph.	($10^3/\text{mm}^3$)	7.398±1.397			7.982±1.372
Lymph.	(%)	86.86±1.17			83.78±1.86*
Neutro.	($10^3/\text{mm}^3$)	0.784±0.164			1.176±0.214*
Neutro.	(%)	9.26±1.49			12.42±1.86*
LUC	($10^3/\text{mm}^3$)	0.094±0.064			0.078±0.038
LUC	(%)	1.18±0.83			0.82±0.27
PT	(Sec)	14.84±3.34			15.70±2.71
APTT	(Sec)	23.98±1.48			25.48±1.23

Values are expressed as the mean ± S.D.

* P<0.05 : Significantly different from the control group by t-test / Wilcoxon test.

Table 5-4

Hematology in females (End of recovery test)

Study No. : SBL75-31

Dose(mg/kg)		Control	2.5	25	250
N		5	0	0	5
RBC	($10^6/\text{mm}^3$)	8.074±0.449			8.112±0.157
WBC	($10^3/\text{mm}^3$)	3.446±0.317			3.514±0.780
Ht	(%)	45.00±1.78			44.54±0.58
Hb	(g/dL)	15.40±0.66			15.30±0.39
Plat.	($10^3/\text{mm}^3$)	1113.2±77.9			1037.4±91.2
MCV	(fL)	55.78±1.08			54.94±0.52
MCH	(pg)	19.10±0.37			18.82±0.16
MCHC	(g/dL)	34.20±0.35			34.28±0.52
Ret.	(%)	2.32±0.42			2.08±0.43
Eosino.	($10^3/\text{mm}^3$)	0.064±0.015			0.056±0.015
Eosino.	(%)	1.80±0.45			1.66±0.74
Baso.	($10^3/\text{mm}^3$)	0.000±0.000			0.000±0.000
Baso.	(%)	0.06±0.05			0.04±0.05
Mono.	($10^3/\text{mm}^3$)	0.066±0.017			0.062±0.019
Mono.	(%)	1.92±0.45			1.74±0.50
Lymph.	($10^3/\text{mm}^3$)	2.634±0.281			2.834±0.698
Lymph.	(%)	76.78±7.95			80.34±4.18
Neutro.	($10^3/\text{mm}^3$)	0.652±0.295			0.542±0.157
Neutro.	(%)	18.64±7.31			15.60±3.83
LUC	($10^3/\text{mm}^3$)	0.028±0.015			0.022±0.008
LUC	(%)	0.74±0.34			0.62±0.24
PT	(Sec)	7.70±0.38			7.36±0.09
APTT	(Sec)	18.04±0.86			17.58±0.19

Values are expressed as the mean + S.D.

Not significantly different from the control group by t-test / Wilcoxon test.

Table 6 Abbreviations of blood chemistry parameters

Study No.SBL75-31

Blood Chemistry

ASAT	(IU/L)	Aspartate aminotransferase
ALAT	(IU/L)	Alanine aminotransferase
ALP	(IU/L)	Alkaline phosphatase
LDH	(IU/L)	Lactate dehydrogenase
CPK	(IU/L)	Creatine phosphokinase
T.Bil.	(mg/dL)	Total bilirubin
T.Prot.	(g/dL)	Total protein
Albumin	(g/dL)	Albumin
T.Chol.	(mg/dL)	Total cholesterol
TGL	(mg/dL)	Triglyceride
Glucose	(mg/dL)	Glucose
BUN	(mg/dL)	Blood urea nitrogen
Creat.	(mg/dL)	Creatinine
IP	(mg/dL)	Inorganic phosphorus
Ca	(mg/dL)	Calcium
Na	(mEq/L)	Sodium
K	(mEq/L)	Potassium
Cl	(mEq/L)	Chloride
TBA	(μ mol/L)	Total bile acid

Protein fraction

Albumin	(%)	Albumin
A1-glob.	(%)	Alpha-1 globulin
A2-glob.	(%)	Alpha-2 globulin
B-glob.	(%)	Beta globulin
G-glob.	(%)	Gamma globulin
A/G		Albumin / Globulin

Table 6-1 Blood chemistry in males (End of drug administration)

Study No. : SBL75-31

Dose(mg/kg)	Control	2.5	25	250.
N	5	5	5	5
ASAT (IU/L)	115.6+23.0	92.4+17.7	135.8+28.1	120.8+23.1
ALAT (IU/L)	38.8±3.7	39.2±2.9	58.2±25.5*	48.8±7.5
ALP (IU/L)	539.0±57.3	475.6±77.7	616.8±177.8	942.6±149.6**
LDH (IU/L)	2106.6±753.8	1235.8±824.0	2751.8±1313.4	2255.6±792.4
CPK (IU/L)	836.6±225.3	441.8±232.4	826.8±314.2	694.0±248.4
T.Bil. (mg/dL)	0.052±0.008	0.048±0.016	0.046±0.013	0.024±0.009**
T.Prot. (g/dL)	5.60±0.10	6.04±0.27	6.26±0.41**	5.92±0.34
Albumin (g/dL)	4.10±0.10	4.54±0.25	5.18±0.43**	5.00±0.24**
T.Chol. (mg/dL)	68.0±6.9	58.4±12.8	64.0±7.3	61.2±16.5
TGL (mg/dL)	51.0±16.0	36.2±10.1	45.0±14.8	57.2±11.5
Glucose (mg/dL)	186.2±14.0	173.2±14.3	190.4±14.6	198.2±27.1
BUN (mg/dL)	20.74±1.17	19.68±2.59	21.78±1.85	21.34±3.76
Creat. (mg/dL)	0.312±0.053	0.274±0.022	0.226±0.037**	0.248±0.022*
IP (mg/dL)	7.106±0.352	7.004±0.515	7.848±0.606	7.490±0.692
Ca (mg/dL)	8.94±0.26	9.28±0.16	9.58±0.20**	9.18±0.24
Na (mEq/L)	141.0±0.7	142.4±0.5	142.2±1.6	140.2±0.4
K (mEq/L)	4.46±0.17	4.40±0.41	4.54±0.27	4.62±0.18
Cl (mEq/L)	103.0±1.4	104.6±1.7	103.6±0.9	102.8±0.8
Albumin (%)	51.48±2.34	53.26±1.80	58.56±2.53**	61.00±1.66**
A1-glob. (%)	20.38±2.69	20.66±2.51	19.14±2.91	18.14±1.16
A2-glob. (%)	9.44±0.51	9.00±0.33	7.76±0.21**	7.60±0.37**
B-glob. (%)	14.52±0.92	12.88±1.02**	10.56±0.56**	9.02±0.30**
G-glob. (%)	4.18±1.03	4.20±0.31	3.98±0.76	4.24±0.80
A/G	1.058±0.098	1.142±0.086	1.418±0.141**	1.568±0.106**
TBA (μ. mol/L)	15.02±7.33	13.16±4.54	24.98±8.23	40.06±44.09

Values are expressed as the mean + S.D.

* P<0.05, ** P<0.01 : Significantly different from the control group by Dunnet's type test / Dunnet's test.

Table 6-2 Blood chemistry in females (End of drug administration)

Study No. : SBL75-31

Dose (mg/kg)	Control	2.5	25	250
N	5	5	5	5
ASAT (IU/L)	130.2±11.3	112.8±37.2	106.4±14.8	103.8±22.6
ALAT (IU/L)	59.0±9.1	42.8±7.8	49.4±9.9	60.2±15.3
ALP (IU/L)	214.8±29.4	185.4±70.5	184.4±56.4	193.8±59.4
LDH (IU/L)	2642.2±802.9	2198.2±1795.1	1632.2±600.4	1347.4±653.2
CPK (IU/L)	794.4±425.0	588.4±457.5	445.6±137.3	333.0±156.2
T.Bil. (mg/dL)	0.058±0.016	0.074±0.030	0.044±0.011	0.056±0.013
T.Prot. (g/dL)	5.74±0.31	5.60±0.27	5.54±0.36	5.50±0.22
Albumin (g/dL)	4.46±0.29	4.36±0.15	4.38±0.31	4.30±0.19
T.Chol. (mg/dL)	79.6±16.8	58.4±3.2*	57.6±13.3*	64.2±12.9
TGL (mg/dL)	25.4±6.9	23.0±15.0	21.2±15.1	17.8±13.8
Glucose (mg/dL)	109.0±15.8	108.6±13.2	119.8±6.7	115.0±24.1
BUN (mg/dL)	26.14±8.24	17.28±5.27	19.82±4.06	18.90±4.97
Creat. (mg/dL)	0.308±0.044	0.290±0.040	0.330±0.029	0.282±0.028
IP (mg/dL)	6.614±0.971	5.620±0.963	6.274±0.867	6.020±0.726
Ca (mg/dL)	8.94±0.67	8.88±0.47	9.02±0.24	9.16±0.54
Na (mEq/L)	140.2±0.8	139.6±1.1	140.2±1.1	139.8±1.9
K (mEq/L)	4.10±0.16	4.22±0.16	4.00±0.14	3.92±0.19
Cl (mEq/L)	101.2±2.4	100.4±1.5	101.4±2.5	101.0±1.6
Albumin (%)	55.02±1.84	54.22±2.05	55.48±0.75	55.44±1.82
A1-glob. (%)	17.82±2.14	19.20±1.42	17.78±2.24	17.56±1.30
A2-glob. (%)	8.76±1.21	8.84±0.90	7.92±0.75	8.34±0.32
B-glob. (%)	13.46±0.92	13.34±0.90	13.68±0.76	13.38±0.99
G-glob. (%)	4.94±1.20	4.40±0.42	5.14±0.46	5.28±0.41
A/G	1.226±0.090	1.188±0.104	1.246±0.036	1.246±0.092
TBA (μ mol/L)	43.04±41.60	25.78±12.77	23.02±8.12	17.00±8.51

Values are expressed as the mean ± S.D.

* p<0.05 : significantly different from the control group by Dunnet's type test / Dunnet's test.

Table 6-3 Blood chemistry in males (End of recovery test)

Study No. : SBL75-31

Dose(mg/kg)	Control	2.5	25	250
N	5	0	0	5
ASAT (IU/L)	87.4±10.8			107.8±25.3
ALAT (IU/L)	34.0±4.4			74.2±35.0
ALP (IU/L)	316.8±65.4			343.0±38.7
LDH (IU/L)	756.8±223.1			838.4±309.5
CPK (IU/L)	384.6±98.9			353.8±127.5
T.Bil. (mg/dL)	0.054±0.023			0.040±0.012
T.Prot. (g/dL)	5.94±0.09			6.50±0.14**
Albumin (g/dL)	4.28±0.13			4.96±0.29**
T.Chol. (mg/dL)	55.4±16.8			96.6±30.3*
TGL (mg/dL)	20.0±5.3			37.0±27.0
Glucose (mg/dL)	194.4±22.7			183.4±16.1
BUN (mg/dL)	20.96±1.59			22.50±2.21
Creat. (mg/dL)	0.412±0.038			0.340±0.044*
IP (mg/dL)	7.568±0.159			7.552±0.674
Ca (mg/dL)	9.24±0.15			9.38±0.13
Na (mEq/L)	140.6±1.1			140.6±0.9
K (mEq/L)	4.36±0.19			4.50±0.48
Cl (mEq/L)	103.2±1.9			104.2±1.3
Albumin (%)	51.94±1.36			53.58±3.75
A1-glob. (%)	20.66±2.46			20.86±3.46
A2-glob. (%)	9.22±0.49			8.30±0.45*
B-glob. (%)	13.60±0.84			12.96±0.69
G-glob. (%)	4.58±0.89			4.30±0.60
A/G	1.084±0.058			1.168±0.174
TBA (μ mol/L)	15.44±8.92			21.42±19.90

Values are expressed as the mean + S.D.

* P<0.05 , ** P<0.01 : Significantly different from the control group by t-test / Wilcoxon test.

Table 6-4

Blood chemistry in females (End of recovery test)

Study No. : SBL75-31

Dose(mg/kg)	Control	2.5	25	250
N	5	0	0	5
ASAT (IU/L)	84.4±9.2			74.8±14.3
ALAT (IU/L)	24.4±6.1			21.8±4.0
ALP (IU/L)	167.4±29.2			188.6±38.3
LDH (IU/L)	1178.2±667.1			967.8±514.9
CPK (IU/L)	342.6±174.9			303.0±109.5
T.Bil. (mg/dL)	0.062±0.004			0.084±0.026
T.Prot. (g/dL)	6.18±0.33			6.42±0.30
Albumin (g/dL)	4.98±0.20			5.26±0.30
T.Chol. (mg/dL)	69.2±4.1			60.2±8.1
TGL (mg/dL)	17.2±4.2			19.2±6.5
Glucose (mg/dL)	162.6±9.9			161.0±13.0
BUN (mg/dL)	21.70±2.61			21.20±4.48
Creat. (mg/dL)	0.382±0.034			0.366±0.025
IP (mg/dL)	4.682±0.515			4.638±1.243
Ca (mg/dL)	9.12±0.29			9.26±0.23
Na (mEq/L)	140.6±0.9			140.4±1.1
K (mEq/L)	3.92±0.24			3.92±0.22
Cl (mEq/L)	105.6±1.1			106.6±1.1
Albumin (%)	59.66±2.81			59.06±0.26
A1-glob. (%)	13.06±2.91			14.82±0.94
A2-glob. (%)	7.36±0.59			7.50±1.05
B-glob. (%)	13.80±1.00			13.68±0.88
G-glob. (%)	6.12±1.26			4.94±0.54
A/G	1.488±0.175			1.438±0.013
TBA (μ mol/L)	14.86±12.28			25.18±17.85

Values are expressed as the mean + S.D.

Not significantly different from the control group by t-test / Wilcoxon test.

Table 7-1 Gross pathological findings in males (End of drug administration)

Study No. : SBL75-31

Dose (mg/kg)	Control	2.5	25	250
No. of animals	10	10	10	10
Normal	10	10	10	9
Lung: Red focus	0	0	0	1

73

Table 7-2 Gross pathological findings in females (End of drug administration)

Study No. : SBL75-31

Dose (mg/kg)	Control	2.5	25	250
No. of animals	10	10	10	10
No. of dams	9	10	10	10
Normal	9	10	10	10
No. of non-copulated animal	1	0	0	0
Normal	1	0	0	0

Table 7-3 Gross pathological findings in males (End of recovery test)

Study No. : SBL75-31

Dose (mg/kg)	Control	250
No. of animals	5	5
Normal	4	5
Lung : Red focus	1	0

Table 7-4 Gross pathological findings in females (End of recovery test)

Study No. : SBL75-31

Dose (mg/kg)	Control	250
No. of animals	5	5
Normal	5	5

Table 8 Abbreviations of organ weights

Study No. SBL75-31

Organ weight

Epididy. Sem. Vesic.	Epididymis Seminal vesicle
-R	(Right)
-L	(Left)
-R&L	(Right and Left)

77

Table 8-1

Organ weight in males (End of drug administration)

Study No. : SBL75-31

Dose (mg/kg)		Control	2.5	25	250
	N	5	5	5	5
Adrenal-R	(mg)	29.46±6.49	28.76±4.44	29.54±2.67	24.92±2.33
Adrenal-L	(mg)	31.74±3.86	33.34±5.37	31.94±4.54	25.84±1.62
Adrenal-R&L	(mg)	61.20±9.48	62.10±9.20	61.48±6.92	50.76±3.21
Testis-R	(mg)	1613.6±63.3	1685.0±64.1	1501.4±132.3	1494.4±108.4
Testis-L	(mg)	1615.6±82.5	1700.6±112.8	1512.8±150.9	1504.0±146.5
Testis-R&L	(mg)	3229.2±141.5	3385.6±174.1	3014.2±281.9	2998.4±253.2
Thymus	(mg)	391.2±90.3	401.2±104.4	411.8±173.7	396.2±87.6
Spleen	(mg)	852.8±81.9	957.4±204.7	908.0±218.0	790.0±61.5
Brain	(mg)	2069.4±70.2	2093.0±63.3	2061.4±109.4	2001.2±88.0
Heart	(mg)	1413.4±69.9	1524.8±108.5	1440.2±156.4	1418.8±108.1
Liver	(g)	14.812±1.426	16.456±1.701	20.110±3.759*	24.110±2.602**
Kidney-R	(mg)	1572.6±92.6	1765.2±166.8	1761.0±195.5	1643.6±116.9
Kidney-L	(mg)	1595.6±161.4	1725.4±145.2	1739.0±206.0	1691.4±69.1
Kidney-R&L	(mg)	3168.2±248.7	3490.6±308.6	3500.0±398.5	3335.0±182.2
Epididy.-R	(mg)	620.8±23.6	635.4±36.1	596.0±54.2	613.8±63.4
Epididy.-L	(mg)	640.6±43.9	633.0±31.8	636.4±84.2	627.6±73.0
Epididy.-R&L	(mg)	1261.4±65.7	1268.4±58.7	1232.4±137.8	1241.4±134.0
Sem. Vesic.	(mg)	1712.4±178.5	1686.4±140.3	1704.4±210.8	1599.8±115.5
Prostate	(mg)	1365.8±92.7	1250.0±96.6	1415.8±339.7	1394.4±191.4

Values are expressed as the mean + S.D.

* P<0.05 , ** P<0.01 : Significantly different from the control group by Dunnet's type test / Dunnet's test.

Table 8-2

Organ weight in females (End of drug administration)

Study No. : SBL75-31

Dose (mg/kg)		Control	2.5	25	250
N		5	5	5	5
Adrenal-R	(mg)	45.28±6.52	41.40±4.69	41.42±4.94	42.72±1.73
Adrenal-L	(mg)	50.44±9.02	43.64±6.14	43.84±5.39	46.74±2.61
Adrenal-R&L	(mg)	95.72±15.21	85.04±10.30	85.26±10.30	89.46±3.98
Ovary-R	(mg)	50.30±7.29	47.90±4.66	49.22±11.74	53.64±6.91
Ovary-L	(mg)	45.60±6.62	48.46±5.16	46.38±0.89	51.24±17.35
Ovary-R&L	(mg)	95.90±10.44	96.36±6.23	95.60±11.60	104.88±18.78
Thymus	(mg)	219.0±40.2	272.2±59.8	247.2±87.2	252.8±64.2
Spleen	(mg)	715.8±177.7	713.0±125.0	665.6±172.1	748.8±61.7
Brain	(mg)	1962.2±38.4	1963.0±61.0	1967.2±90.9	1939.6±61.2
Heart	(mg)	1059.6±142.1	1003.0±35.6	984.0±76.3	1011.0±98.0
Liver	(g)	9.892±1.644	8.992±0.665	9.158±0.692	9.686±0.542
Kidney-R	(mg)	1082.0±141.9	1040.4±69.2	984.8±106.5	1025.2±25.1
Kidney-L	(mg)	1082.0±138.8	1029.4±74.0	991.6±108.1	1008.2±19.9
Kidney-R&L	(mg)	2164.0±279.6	2069.8±140.5	1976.4±213.1	2033.4±28.6

Values are expressed as the mean ± S.D.

Not significantly different from the control group by Dunnet's type test / Dunnet's test.

Table 8-3

Organ weight in males (End of recovery test)

Study No. : SBL75-31

Dose(mg/kg)		Control	2.5	25	250
N		5	0	0	5
Adrenal-R (mg)		30.28±4.07			32.00±4.41
Adrenal-L (mg)		29.96±4.22			33.10±6.34
Adrenal-R&L (mg)		60.24±8.16			65.10±10.65
Testis-R (mg)		1497.8±362.4			1434.4±375.4
Testis-L (mg)		1480.0±341.0			1416.6±370.9
Testis-R&L (mg)		2977.8±700.1			2851.0±744.8
Thymus (mg)		370.6±70.6			333.8±49.2
Spleen (mg)		833.8±85.2			868.2±151.5
Brain (mg)		2104.8±32.3			2161.0±61.7
Heart (mg)		1471.2±77.7			1584.6±46.7*
Liver (g)		13.318±1.013			15.678±1.709*
Kidney-R (mg)		1643.0±131.0			1663.8±171.6
Kidney-L (mg)		1620.0±101.4			1706.4±207.6
Kidney-R&L (mg)		3263.0±225.1			3390.2±377.3
Epididy.-R (mg)		647.6±121.0			621.2±82.9
Epididy.-L (mg)		628.8±116.3			597.8±79.4
Epididy.-R&L (mg)		1276.4±235.5			1219.0±161.6
Sem. Vesic. (mg)		1650.0±231.7			1629.6±377.5
Prostate (mg)		1304.4±173.4			1219.6±257.2

Values are expressed as the mean ± S.D.

* P<0.05 : Significantly different from the control group by t-test / Wilcoxon test.

Table 8-4 Organ weight in females (End of recovery test)

Study No. : SBL75-31

Dose (mg/kg)		Control	2.5	25	250
N		5	0	0	5
Adrenal-R (mg)		32.40±1.24			35.26±7.28
Adrenal-L (mg)		34.46±1.62			36.46±6.40
Adrenal-R&L (mg)		66.86±2.13			71.72±13.67
Ovary-R (mg)		42.58±4.16			45.66±5.97
Ovary-L (mg)		41.18±6.73			47.36±16.14
Ovary-R&L (mg)		83.76±8.16			93.02±19.94
Thymus (mg)		323.0±55.0			508.6±384.1
Spleen (mg)		489.6±47.5			511.6±89.6
Brain (mg)		1934.6±111.8			1894.8±86.8
Heart (mg)		906.6±99.7			928.8±85.5
Liver (g)		7.096±0.549			7.544±0.500
Kidney-R (mg)		944.2±78.3			941.0±26.4
Kidney-L (mg)		931.6±83.0			924.6±15.9
Kidney-R&L (mg)		1875.8±153.6			1865.6±26.0

Values are expressed as the mean ± S.D.

Not significantly different from the control group by t-test / Wilcoxon test.

Table 8-5

Relative organ weight in males (End of drug administration)

Study No. : SBL75-31

Dose(mg/kg) N	Control 5	2.5 5	25 5	250 5
Body weight (g)	450.8±34.6	463.4±26.2	454.4±36.7	437.0±10.9
Adrenal-R (mg/100gBW)	6.60±1.56	6.22±0.98	6.56±1.05	5.70±0.46
Adrenal-L (mg/100gBW)	7.08±0.87	7.20±1.21	7.08±1.25	5.90±0.34
Adrenal-R&L (mg/100gBW)	13.64±2.29	13.42±2.06	13.62±2.20	11.60±0.62
Testis-R (mg/100gBW)	359.8±30.0	364.4±21.2	331.6±33.0	341.8±24.9
Testis-L (mg/100gBW)	360.2±32.8	368.0±30.9	334.4±39.8	344.0±33.7
Testis-R&L (mg/100gBW)	719.8±62.3	732.2±51.3	666.0±72.7	686.2±58.2
Thymus (mg/100gBW)	87.4±22.7	86.2±18.6	89.4±31.5	90.8±20.5
Spleen (mg/100gBW)	189.8±19.4	206.0±37.6	198.8±35.3	181.2±17.3
Brain (mg/100gBW)	461.0±34.3	453.0±34.0	457.4±61.2	458.6±30.0
Heart (mg/100gBW)	314.2±11.1	329.4±18.4	316.6±18.2	324.8±23.8
Liver (g/100gBW)	3.284±0.127	3.544±0.198	4.408±0.548*	5.524±0.658**
Kidney-R (mg/100gBW)	350.8±39.4	380.8±24.8	387.2±22.4	376.2±27.9
Kidney-L (mg/100gBW)	355.6±44.2	372.8±27.0	382.4±23.5	387.6±18.7
Kidney-R&L (mg/100gBW)	706.4±81.9	753.2±50.6	769.4±44.6	763.4±45.2
Epididym.-R (mg/100gBW)	138.4±12.3	137.0±4.5	131.4±7.5	140.0±12.6
Epididym.-L (mg/100gBW)	142.8±14.7	136.6±7.9	139.8±11.3	143.6±15.7
Epididym.-R&L (mg/100gBW)	281.2±26.5	274.2±10.4	271.2±17.9	284.0±28.0
Sem. Vesic. (mg/100gBW)	382.6±60.3	365.2±40.4	375.6±40.3	366.2±26.8
Prostate (mg/100gBW)	304.6±35.2	270.4±24.5	309.2±57.1	318.6±38.1

Values are expressed as the mean + S.D.

* P<0.05 , ** P<0.01 : Significantly different from the control group by Dunnet's type test / Dunnet's test.

Table 8-6

Relative organ weight in females (End of drug administration)

Study No. : SBL75-31

Dose (mg/kg) N	Control 5	2.5 5	25 5	250 5
Body weight (g)	281.6±32.8	290.4±13.6	276.0±14.5	283.0±20.9
Adrenal-R (mg/100gBW)	16.20±2.75	14.28±1.66	15.02±1.60	15.14±0.76
Adrenal-L (mg/100gBW)	17.96±2.71	15.04±2.10	15.88±1.72	16.56±1.02
Adrenal-R&L (mg/100gBW)	34.14±5.23	29.34±3.59	30.90±3.31	31.70±1.60
Ovary-R (mg/100gBW)	18.10±3.61	16.54±2.06	17.84±4.11	18.96±1.85
Ovary-L (mg/100gBW)	16.42±3.19	16.66±1.07	16.84±0.71	17.96±5.11
Ovary-R&L (mg/100gBW)	34.54±5.90	33.20±1.89	34.68±4.16	36.94±4.45
Thymus (mg/100gBW)	77.6±7.8	93.6±18.6	90.2±32.9	90.2±26.5
Spleen (mg/100gBW)	252.0±44.0	246.0±46.5	239.8±51.6	264.6±15.5
Brain (mg/100gBW)	705.6±97.9	677.2±43.8	715.6±67.6	688.4±57.5
Heart (mg/100gBW)	376.2±18.5	345.6±11.9	356.6±21.7	358.0±35.1
Liver (g/100gBW)	3.506±0.365	3.098±0.185*	3.318±0.099	3.432±0.203
Kidney-R (mg/100gBW)	385.0±30.7	358.0±13.3	356.4±27.6	363.8±27.8
Kidney-L (mg/100gBW)	385.2±37.0	354.4±20.4	359.0±30.4	357.8±22.4
Kidney-R&L (mg/100gBW)	770.2±67.4	712.8±32.5	715.2±57.2	721.4±48.8

Values are expressed as the mean + S.D.

* P<0.05 : Significantly different from the control group by Dunnet's type test / Dunnet's test.

Table 8-7 Relative organ weight in males (End of recovery test)

Study No. : SBL75-31

Dose(mg/kg)	Control	2.5	25	250
N	5	0	0	5
Body weight (g)	474.2±22.8			457.0±25.2
Adrenal-R (mg/100gBW)	6.38±0.75			7.00±0.96
Adrenal-L (mg/100gBW)	6.30±0.81			7.26±1.37
Adrenal-R&L (mg/100gBW)	12.70±1.52			14.24±2.37
Testis-R (mg/100gBW)	317.6±82.5			311.8±70.5
Testis-L (mg/100gBW)	313.8±78.6			307.8±70.0
Testis-R&L (mg/100gBW)	631.4±160.4			619.2±140.6
Thymus (mg/100gBW)	79.0±18.3			73.2±11.9
Spleen (mg/100gBW)	176.2±20.8			189.8±29.8
Brain (mg/100gBW)	444.4±18.2			473.8±22.4
Heart (mg/100gBW)	310.0±1.9			347.2±9.3**
Liver (g/100gBW)	2.810±0.188			3.434±0.360**
Kidney-R (mg/100gBW)	346.8±27.1			368.0±26.7
Kidney-L (mg/100gBW)	342.0±24.0			373.0±32.9
Kidney-R&L (mg/100gBW)	689.0±49.5			741.0±58.7
Epididym.-R (mg/100gBW)	137.0±28.3			135.8±16.0
Epididym.-L (mg/100gBW)	133.0±26.3			130.8±14.6
Epididym.-R&L (mg/100gBW)	270.2±54.2			266.6±30.9
Sem. Vesic. (mg/100gBW)	348.0±43.8			357.6±89.0
Prostate (mg/100gBW)	275.6±40.9			267.6±62.3

Values are expressed as the mean ± S.D.

* P<0.01 : Significantly different from the control group by t-test / Wilcoxon test.

Table 8-8

Relative organ weight in females (End of recovery test)

Study No. : SBL75-31

Dose(mg/kg) N	Control 5	2.5 0	25 0	250 5
Body weight (g)	268.2±21.4			283.0±17.5
Adrenal-R (mg/100gBW)	12.12±0.90			12.46±2.47
Adrenal-L (mg/100gBW)	12.94±1.17			12.90±2.18
Adrenal-R&L (mg/100gBW)	25.04±1.99			25.36±4.64
Ovary-R (mg/100gBW)	15.98±2.33			16.22±2.50
Ovary-L (mg/100gBW)	15.32±1.93			16.88±6.32
Ovary-R&L (mg/100gBW)	31.32±3.15			33.12±8.11
Thymus (mg/100gBW)	120.0±12.3			174.2±115.9
Spleen (mg/100gBW)	183.6±22.6			180.8±30.5
Brain (mg/100gBW)	724.2±57.3			670.2±25.4
Heart (mg/100gBW)	338.0±21.6			328.4±30.9
Liver (g/100gBW)	2.652±0.184			2.664±0.107
Kidney-R (mg/100gBW)	354.2±44.9			333.0±12.9
Kidney-L (mg/100gBW)	349.0±39.4			327.8±22.4
Kidney-R&L (mg/100gBW)	703.2±82.6			660.8±34.6

Values are expressed as the mean + S.D.

Not significantly different from the control group by t-test / Wilcoxon test.

Table 9-1 Histopathological findings in males [H.E. staining] (End of drug administration)

Study No.: SBL75-31

Dose (mg/kg)	Control	250
No. of animals	5	5
Normal	0	0
Adrenal (Left)		
Vacuolation, zona fasciculata cell	2	2
Adrenal (Right)		
Vacuolation, zona fasciculata cell	2	2
Heart		
Fibrosis, myocardium, left ventricle	1	1
Mononuclear cell infiltration, myocardium, left ventricle	0	2
Mononuclear cell infiltration, myocardium, right ventricle	1	0
Kidney (Left)		
Basophilia, tubule	3	3
Hyaline cast, tubular lumen	1	0
Mineralization, cortex	1	0
Mononuclear cell infiltration, cortex	1	0
Vacuolation, tubular epithelium	1	0

Table 9-1 (Continued)

Study No.: SBL75-31

Dose (mg/kg)	Control	250
No. of animals	5	5
Kidney (Right)		
Basophilia, tubule	1	2
Mononuclear cell infiltration, cortex	1	0
Lung (Including bronchus, left)		
Foam cell accumulation, alveolus	2	1
Osseous metaplasia	1	0
Lung (Including bronchus, right)		
Foam cell accumulation, alveolus	1	2
Mineralization, arterial wall	2	0
Mononuclear cell infiltration, alveolus	1	0
Lung (Gross abnormal site, right)		
Inflammatory cell infiltration, alveolus, focal	0	1

87

Table 9-2 Histopathological findings in females [H.E. staining] (End of drug administration)

Study No.: SBL75-31

Dose (mg/kg)	Control	250
No. of animals	5	5
Normal	1	0
Kindney (Left)		
Basophilia, tubule	3	0
Mineralization, cortico-medullary junction	0	1
Mononuclear cell infiltration, cortex	1	0
Kindney (Right)		
Eosinophil infiltration, transitional epithelium, pelvis	1	0
Foreign material, pelvic lumen	1	0
Mineralization, cortico-medullary junction	0	1
Mononuclear cell infiltration, cortex	1	0

Table 9-2 (Continued)

Study No.: SBL75-31

Dose (mg/kg)	Control	250
No. of animals	5	5
Lung (Including bronchus, left)		
Foam cell accumulation, alveolus	1	1
Inflammatory cell infiltration, perivasular	1	0
Proliferation, alveolar epithelium	1	0
Lung (Including bronchus, right)		
Foam cell accumulation, alveolus	1	2
Granuloma	1	0
Mineralization, arterial wall	0	3
Lymph node (Mesenteric)		
Increase, dendritic cell-like cell	0	1
Trachea		
Squamous metaplasia, ciliated epithelium	1	0

Table 9-3 Histopathological findings in males [Testis, PAS-Hematoxylin staining] (End of drug administration)

Study No.: SBL75-31

Dose (mg/kg)	Control	250
No. of animals	5	5
Normal	5	5

Table 9-4 Histopathological findings in animals [Liver, H.E. staining] (End of drug administration) Study No.: SBL75-31

Male

Dose (mg/kg)	Control	2.5	25	250
No. of animals	5	5	5	5
Liver				
Normal	1	3	3	3
Bile duct proliferation, focal	0	0	0	1
Mononuclear cell infiltration	2	2	2	1
Vacuolation, hepatocyte	2	0	0	0

Female

Dose (mg/kg)	Control	2.5	25	250
No. of animals	5	5	5	5
Liver				
Normal	3	3	3	5
Mononuclear cell infiltration	1	1	2	0
Vacuolation, hepatocyte	1	1	0	0

Table 10-1 Clinical signs in pups (F1) - Lactation period

Study No. : SBL75-31

Group	Control	2.5	25	250
Dose (mg/kg)				
No. of dams	9	10	10	10
No. of live pups at birth	126	139	128	139
No. of live pups at day 4	126	137	125	136
Clinical signs				
No. of pups(No. of dams)				
Normal	126 (9)	139 (10)	128 (10)	139 (10)
Death(No. of dams with total litter loss)	0 (0)	0 (0)	0 (0)	0 (0)

Table 10-2 External findings at birth (F1)

Study No. : SBL75-31

Group Dose (mg/kg)	Control	2.5	25	250
No. of dams	9	10	10	10
No. of pups	126	139	128	139
External findings in pups				
Malformations (%)	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]

(%) : Litter - basis analysis
 []:No. of pups with malformations
 Not significantly different from control.

Table 11 Development of pups (F1) up to Day 4 after birth

Study No. : SBL75-31

Dose (mg/kg)	Control	2.5	25	250
Pregnant animal	9	10	10	10
Duration of gestation (day)	21.89 ± 0.42	21.94 ± 0.30	21.95 ± 0.37	22.00 ± 0.24
Delivery animal	9	10	10	10
Gestation index (%)	100.0	100.0	100.0	100.0
No. of corpora lutea	16.1 ± 1.9	15.7 ± 1.8	15.3 ± 1.5	16.0 ± 1.9
No. of implantations	15.3 ± 1.7	14.8 ± 1.5	14.1 ± 1.2	14.2 ± 3.2
Implantation index (%) a)	95.36 ± 5.02	94.91 ± 10.81	92.54 ± 6.97	90.72 ± 16.91
At birth				
No. of born	14.1 ± 2.2	14.0 ± 1.9	12.8 ± 2.0	14.0 ± 3.1
No. of live	14.0 ± 2.2	13.9 ± 1.9	12.8 ± 2.0	13.9 ± 2.9
Live birth index (%) b)	91.07 ± 7.23	93.80 ± 7.00	91.01 ± 13.84	96.45 ± 5.69
Viability index (%) c)	99.21 ± 2.37	99.29 ± 2.25	98.82 ± 3.73	98.80 ± 2.55
Sex ratio (Female/Total)	0.53 ± 0.09	0.50 ± 0.15	0.53 ± 0.09	0.61 ± 0.16
At 4 days				
No. of live	14.0 ± 2.2	13.7 ± 1.6	12.5 ± 2.1	13.6 ± 3.0
Viability index (%) d)	100.00 ± 0.00	98.79 ± 2.55	97.55 ± 3.96	97.73 ± 3.67
Sex ratio (Female/Total)	0.53 ± 0.09	0.49 ± 0.14	0.54 ± 0.10	0.61 ± 0.15

a) Implantation index : (No. of implantations / No. of corpora lutea) × 100

b) Live birth index : (No. of live at birth / No. of implantations) × 100

c) Viability index Day 0 : (No. of live at birth / No. of born at birth) × 100

d) Viability index Day 4 : (No. of live at 4 days / No. of live at birth) × 100

Not significantly different from the control group by Dunnet's test / Dunnet's type test.

Not significantly different from the control group by Fisher's exact test.

Table 12

Body weight of pups (F1) - Lactation period (mean \pm S.D. , g)

Study No. : SBL75-31

Dose (mg/kg)	Control	2.5	25	250
No. of dams	9	10	10	10
Postnatal day				
0 : Male	6.5 \pm 0.5 (58)	6.5 \pm 0.5 (70)	6.8 \pm 0.3 (60)	6.5 \pm 0.4 (58)
Female	6.0 \pm 0.4 (58)	6.2 \pm 0.5 (69)	6.3 \pm 0.4 (68)	6.1 \pm 0.4 (81)
4 : Male	9.3 \pm 1.1 (58)	9.4 \pm 0.9 (70)	10.2 \pm 0.7 (58)	9.6 \pm 1.4 (56)
Female	8.9 \pm 1.0 (58)	9.0 \pm 0.8 (67)	9.7 \pm 0.7 (67)	9.1 \pm 1.5 (80)

() : No. of pups (F1)

Not significantly different from the control group by Dunnet's type test / Dunnet's test

Table 13 Gross pathological findings in pups (F1) at Day 4 after birth

Study No. : SBL75-31

Dose (mg/kg)	Control	2.5	25	250
No. of dams (F0)	9	10	10	10
No. of pups (F1)	126	137	125	136
External findings				
Malformations				
Mean frequencies (%)	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]
Visceral findings				
Malformations				
Mean frequencies (%)	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]	0.00 ± 0.00 [0]

(*) : Litter - basis analysis

[]:No. of pups with malformations

Not significantly different from control.